| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
|
| Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Satoshi Shakado, Shotaro Sakisaka, Kazuaki Chayama, Takeshi Okanoue, Joji Toyoda, Namiki Izumi, Akihiro Matsumoto, Tetsuo Takehara, Akio Ido, Yoichi Hiasa, Kentaro Yoshioka, Hideyuki Nomura, Yoshiyuki Ueno, Masataka Seike and Hiromitsu Kumada |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Japanese Ministry of Health, Welfare and Labour |
|
|
| Corresponding Author |
Satoshi Shakado, MD, Associate Professor, Department of Gastroenterology and Medicine, Faculty of Medicine, Fukuoka University, 7-45-1 Nanakuma, Jonan-ku, Fukuoka City, Fukuoka 814-0180,
Japan. shakado@cis.fukuoka-u.ac.jp
|
| Key Words |
Des-γ-carboxy prothrombin; Hepatocellular carcinoma; Alpha-fetoprotein; Interferon; Hepatitis C virus; Liver cirrhosis; Ribavirin |
| Core Tip |
Interferon (IFN)-based therapy reduces the rate of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C virus (HCV) infection. However, HCC development has frequently been re-ported in HCV-related liver cirrhosis (LC-C) patients who achieved sustained virological response. We conducted a multicenter, retrospective study to evaluate the relationship between clinical factors and HCC development in Japanese LC-C patients treated with IFN and ribavirin therapy. We suggested that the elevation of Alpha-fetoprotein and des-γ-carboxy prothrombin levels at 24 wk after the completion of IFN and ribavirin therapy were strongly associated with the incidence of HCC irrespective of virological response among Japanese LC-C patients.
|
| Publish Date |
2015-11-27 17:14 |
| Citation |
Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H. Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development. World J Hepatol 2015; 7(27): 2757-2764 |
| URL |
http://www.wjgnet.com/1948-5182/full/v7/i27/2757.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v7.i27.2757 |
